Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common ADHD drug improve speech in kids with apraxia?

NCT ID NCT05185583

Symptom relief Sponsor: Murdoch Childrens Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether methylphenidate, a drug often used for ADHD, can help children aged 6 to 12 with childhood apraxia of speech speak more clearly. The trial involved 18 children who took the drug or a placebo in a crossover design. The main goal was to see if the drug improved how well others could understand their speech.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

18 people

The number who actually took part.

Started

Mar 2022

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has childhood apraxia of speech * Aged 6-12 years * Can perform the speech tasks for the trial (able to speak single words and short sentences) * English as a first language * Has adequate hearing * Has a legally acceptable representative capable of understanding the informed consent document and providing consent on their behalf * Passes the health and medical examination including examination of heart rate and blood pressure for age and weight norms * Can commit to the time requirements of the trial * Lives within 250 kilometres of the study site (MCRI) * Able to swallow a capsule * Scores 13 or more out of 27 on either the inattention and/or hyperactivity subscales of the SNAP-IV Parent 18-Item Rating Scale, suggesting clinically significant symptoms of inattention and/or hyperactivity Exclusion Criteria: * Is unable to commit to the time requirements of the trial (8 weeks + 2 days) * Has a diagnosis of severe intellectual disability, or other significant neurodevelopmental conditions (e.g., Fragile X, Down Syndrome, etc.) * Has epilepsy or other seizure disorders * Is taking medication(s) for another health condition(s) that is known to interfere with MPH * Has any contraindication to the stimulant (methylphenidate) medication, including severe anxiety, depression, severe Tourette syndrome, glaucoma, psychotic symptoms, hypertension, congenital heart disease, known past or present diagnosed substance abuse or dependence * Has a score of moderate or high risk of suicidality, assessed with the Columbia Suicidality Severity Rating Scale (C-SSRS) * Has used psychostimulants within the past 3 months (e.g., Ritalin, Concerta, Focalin) * Lives more than 250 kilometres from the study site * Unable to swallow a capsule

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Childhood apraxia of speech are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

apraxia attention deficit hyperactivity disorder, inattentive type childhood apraxia of speech Speech Intelligibility

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Childhood apraxia of speech

Contacts and locations

Locations

  • Murdoch Children's Research Institute

    Parkville, Victoria, 3052, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.